VALARTH See Shilpa Medicare in the appOpen in app
SHILPAMED · NSE · Pharmaceuticals

Shilpa Medicare Ltd

What the numbers mean, from its filings and the exchange. Data as of 12 Oct 2026.
Small Cap · AMFI list Jan-Jun 2026 · Vendor sector: Basic Materials
fair low confidence No valuation within 120 days; P/E 65.1 vs peers 41.9 (16th of 22); P/B 2.5 vs peers 5.4 (4th of 25).
Statements through FY2026Prices adjusted for corporate actionsNot yet reviewed by the adversarial model

What is Shilpa Medicare's share price today?

Shilpa Medicare last traded at ₹1,013.90 on the NSE, as of 12 Oct 2026, 11:00 pm IST, down 0.8% on the day, up 179.8% over a year. Its 52-week range is ₹260 to ₹1,095. The live price is in the app.

₹1,013.90 −0.8% today
+179.8% over 1 year · NSE, as of 12 Oct 2026, 11:00 pm IST
60 month-end closes, 31 Jul 2021 to 30 Sep 2026, adjusted for splits and bonuses
52-week range90% of the way up
Low ₹260High ₹1,095

What is Shilpa Medicare's market cap?

Shilpa Medicare's market capitalisation is about ₹19,983 crore: what it would cost to buy every share at today's price. That makes it the 121st largest small cap company we cover.

₹19,983 Cr Small Cap121st largest small cap company
Small Cap means the companies ranked 251 and below by size, under SEBI's rules. Shares in issue are worked out from the market cap and the price. What market cap tells you →

Key facts

From the exchange
Symbol
NSE: SHILPAMED
ISIN
INE790G01031
Cap bucket
Small Cap, 121st largest by market cap
Industry (NSE)
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
Listed since
2009
Futures and options
Not traded

Is Shilpa Medicare overvalued?

Fair, with low confidence: no valuation within 120 days; P/E 65.1 vs peers 41.9 (16th of 22); P/B 2.5 vs peers 5.4 (4th of 25).

Valuation

Latest price and trailing 12 months
P/E 65.08
vs peers 41.9 · 16th of 22
Price divided by last year's earnings per share: how many years of today's profit you pay for. Learn more →
P/B 2.51
vs peers 5.4 · 4th of 25
Price divided by book value per share: what you pay for each rupee of net assets on the balance sheet. Learn more →
Market cap ₹19,983 Cr
Total market value of all shares, in ₹ crore. Learn more →
Dividend yield 0.2%
vs peers 0.6% · 14th of 15
Last year's dividends as a share of today's price. Learn more →
PEG (vendor) 6.26
vs peers 4.1 · 10th of 16
P/E divided by the vendor's earnings growth figure, which it does not disclose; a P/E adjusted for how fast profits grow. Learn more →
PEG on our 3-year EPS growth Not available
P/E divided by the 3-year EPS growth rate from the stored accounts. Learn more →
3 models could be judged
Skipped — Fair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored

Our valuation range

🔒 Pro
Value range, implied growth at today's price, and the nine models behind it: in the app.

Is Shilpa Medicare a quality business?

Quality score 41.1, 17th of 24 in its peer set; CLEAN on 30 of 30 flags judged.

Quality and risk

Data as of 12 Oct 2026
Business quality Not available
The kind of business, which sets the yardstick it is judged by. Learn more →
Quality score 41.1
vs peers 52.3 · 17th of 24
Returns, margins, leverage and consistency against its peers, out of 100. Learn more →
Risk level CLEAN
30 of 30 flags judged
From flags on debt, earnings quality, dilution and price swings. Learn more →

Profitability

ROE 3.9%
vs peers 15.4% · 22nd of 25
Return on equity: profit as a share of shareholders' money. Learn more →
ROCE 4.8%
vs peers 18.5% · 23rd of 25
Return on capital employed: operating profit as a share of all the capital in the business, debt and equity. Learn more →
Profit margin 17.1%
vs peers 13.3% · 9th of 24
Profit after everything, as a share of revenue. Learn more →
EPS ₹12.44
Trailing 12 months
Profit for each share over the last 12 months.

Scorecard

🔒 Pro
Health scores and red flags with their values and history: in the app.
See the scorecard →
Inside the app

Get a sneak peek of Valarth

Start freeStart free
A Valarth stock page: the share price with its chart and 52-week range, valuation and profitability figures, and a scorecard of health checks.
Stock pagePrice, valuation, profitability and a scorecard of health checks for every company, each figure explained.
The Valarth stock screener: a table of companies with price, market cap, P/E, P/B, PEG, EPS and ROE, and filters down the left.
ScreenerEvery listed company, filtered on 212 figures, each with a plain-language lesson beside it.
The Valarth AI Screener answering 'Which companies will benefit from India's Project 75 submarine programme?' with a basket of four naval shipbuilders and a written thesis.
AI ScreenerAsk a question in plain English, like which companies benefit from India's Project 75. It reads the intent, builds the screen and writes the thesis.
A Valarth business-model card for State Bank of India, with a plain-language summary and statements verified against the filing.
Business modelHow a company makes money and what can hurt it, each statement checked against its annual report.
Valarth's Before the Bell edition, with the day's headline, regulator notes and sector moves.
Before the BellA morning edition before the market opens: what moved, which rule changed, and what it means for your holdings.

Has Shilpa Medicare made money for shareholders?

Yes: +179.8% over one year and +30.3% a year over five years.

Shareholder returns

1-year return +179.8%
Price only
What the share price did over the last 12 months. Learn more →
5-year return +30.3% a year
Price only
Yearly average price return over five years, bonuses and splits adjusted. Learn more →
Wealth destroyer No
Five-year total return — price CAGR on bonus- and split-adjusted closes plus the dividend yield — below the 7% a bank fixed deposit paid. Learn more →

Returns

3Y and 5Y are yearly averages
1W
−0.9%
1M
+12.0%
3M
+62.1%
6M
+145.7%
1Y
+179.8%
3Y
+80.9%
5Y
+30.3%

Does Shilpa Medicare pay a dividend?

Yes. Shilpa Medicare's dividend yield is 0.17% at the latest price; the last payout was ₹0.60 a share, ex-dividend 4 Sep 2026.

Dividends

Per share, by ex-dividend date
Dividend yield0.17%
The past 12 months' dividends as a share of today's price.
4 Sep 2026 · Final₹0.60
17 Sep 2025 · Final₹0.50
19 Sep 2022 · Final₹0.55
20 Sep 2021 · Final₹0.55
16 Mar 2020 · Interim₹0.55
Payout ratio🔒 In the app
The share of profit paid out as dividends; a very high share leaves little to reinvest.
Dividend growth, 5 years🔒 In the app
How fast the dividend per share has grown a year.
Years without a miss🔒 In the app
How many years in a row a dividend has been paid.

Is Shilpa Medicare growing?

Revenue 3 years 14.5% a year; revenue 5 years 8.3% a year; profit 5 years 37.4% a year.

Growth

Statements through FY2026 (Mar-26)
Revenue 3 years 14.5% a year
vs peers 15.9% · 15th of 24
Compound annual growth of revenue over three years. Learn more →
Profit 3 years Not available
Compound annual growth of net profit over three years. Learn more →
Revenue 5 years 8.3% a year
Compound annual growth of revenue over five years. Learn more →
Profit 5 years 37.4% a year
Compound annual growth of net profit over five years. Learn more →
EPS 3 years Not available
Growth in earnings per share, so dilution counts against the company. Learn more →
EPS 5 years 6.5% a year
Growth in earnings per share over five years, so dilution counts against the company. Learn more →
P/E vs own history 31.9%
vs peers 16.4% · 10th of 16
Today's P/E against its own 5-year median; negative is cheaper than its history. Learn more →

How did Shilpa Medicare do last quarter?

Shilpa Medicare reported revenue of ₹466 Cr, up 19.6% on a year earlier and a net profit of ₹101 Cr, up 210.8% in the Jun 2026 quarter.

Latest quarter

Jun 2026
Revenue, latest quarter₹466 Cr
+19.6% on a year earlier
What the company took in over the quarter.
Net profit, latest quarter₹101 Cr
+210.8% on a year earlier
What was left for shareholders after every cost and tax.

How does Shilpa Medicare compare with its peers?

Compared with 24 Pharmaceuticals; 16th of 22 on P/E; 17th of 24 on quality score.

Compared with 24 Pharmaceuticals

24 companies

Shilpa Medicare against its peers

Largest 10 of 24 peers, by market cap
CompanyMarket capP/EP/BROEROCE1YQuality 🔒Rank 🔒
Shilpa Medicare Ltd₹19,983 Cr65.12.53.9%4.8%+179.8%
J B Chemicals & Pharmaceuticals Ltd₹38,677 Cr—8.218.2%24.2%+45.1%
Emcure Pharmaceuticals Ltd₹34,783 Cr34.48.221.8%22.8%+33.8%
Wockhardt Ltd₹32,440 Cr79.26.29.9%9.6%+43.8%
Sai Life Sciences Ltd₹31,606 Cr86.78.214.6%18.7%+71.4%
Neuland Laboratories Ltd₹26,802 Cr53.88.321.5%26.5%+28.0%
Piramal Pharma Ltd₹26,212 Cr—2.29.0%10.8%−0.3%
Acutaas Chemicals Ltd₹25,876 Cr67.012.624.6%32.7%+110.9%
Rubicon Research Ltd₹25,633 Cr87.29.418.6%20.8%+146.5%
Granules India Ltd₹22,238 Cr30.13.810.3%12.5%+44.5%
Caplin Point Laboratories Ltd₹18,705 Cr28.15.621.1%27.0%+22.6%
Peer median—41.95.415.4%18.5%+25.3%
Market cap in rupees crore; P/E and P/B on the latest price; 1Y is the price return over a year. A dash is a figure that does not apply or is not reported.

Full peer comparison

🔒 Pro
Every peer, every figure, the ranks and the quality and forensic scores side by side: in the app.

Who owns Shilpa Medicare?

Shilpa Medicare is held by promoters 40.1%, foreign institutions 12.1%, domestic institutions 8.3%.

Shareholding pattern

Latest filing, percent of shares
Promoters40.1%
The founders and controlling group.
Foreign institutions12.1%
Overseas funds investing through the FPI route.
Domestic institutions8.3%
Indian insurers, banks, pension and mutual funds together.
Mutual funds4.2%
Indian mutual fund schemes; part of domestic institutions.
Retail and others16.9%
Individual investors and everyone else.
Promoter shares pledged🔒 In the app
Promoter shares given as collateral for loans; a high share is a risk to watch.
Holding trend🔒 In the app
Whether promoters, foreign funds and mutual funds have been adding or selling over recent quarters.

What do analysts say about Shilpa Medicare?

4 analysts cover Shilpa Medicare, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Analyst consensus

4 analysts
ConsensusBuy
The rating most covering analysts give the share.
Average target price🔒 In the app
The mean of the analysts' 12-month price targets.
Upside to target🔒 In the app
How far the target sits above or below today's price.
Share rating it a buy🔒 In the app
The share of covering analysts with a buy rating.

What does Shilpa Medicare do and what is it sensitive to?

Shilpa Medicare sells pharmaceutical formulations, including oral films and transdermal patches, and power, and it also licenses out generic formulations to partners for commercialisation in international markets. Sensitive to: USD/EUR/GBP exchange rates.

Business-model card

FY2025 · 37 verified
3Revenue
3Channels
3Regulators
3Reg. dependencies
4Sensitivities
4Costs
2Geographies

Shilpa Medicare sells pharmaceutical formulations, including oral films and transdermal patches, and power, and it also licenses out generic formulations to partners for commercialisation in international markets. Per the filings, its customers include wholesalers, distributors, pharmacy chains, hospitals and government institutions, with exports at 91.58% of turnover.

Revenue by segment

Consolidated, year ended March 31, 2025 (the 'As at 31 March, 2025' column of the products and services table in the consolidated segment note)
Pharmaceutical product and services99.7%
Power sales0.2%
others0.1%

Revenue engine

3 verified
Pharmaceutical product and services revenue
Consolidated-note line showing Rs 1,28,277.13 lakhs for FY2025 against Rs 1,14,783.93 lakhs for FY2024.
Licensing income
Company states it licenses out generic formulations to global partners; per the filing, licensing income is a key segment. Interpretation: it earns upfront, milestone and supply revenue from these partners.
Wind energy sales (related-party table)
Wind energy sales of 272.58 appear in the related-party disclosure. The excerpt does not state the counterparty.

Customers & channels

3 verified
Wholesalers, distributors, doctors and pharmacy chains
Company states its business serves these customer groups, alongside NGOs, hospitals and companies.
Jan Aushadhi pharmacy chains, distributors and government institutions
Named customer groups in the filing's customer list.
International biotech companies (CDMO RFQ flow)
Company states it is seeing growing RFQ flow from international biotech companies, and that CDMO clientele spans global pharma leaders and innovative biotech firms.

Regulators

3 verified
US FDA, EDQM, UK MHRA, SFDA (Saudi Arabia), TGA (Australia) and WHO
Accreditation and GMP status of the Dabaspet facility from these authorities governs its ability to sell into those markets.
Drugs Price Control Order, 2013 (authority not named in the excerpt)
Governs drug pricing; the company lists compliance with it.
Drugs and Cosmetics Act, 1940
Industry-specific law the company lists as applicable to its drug manufacturing.

Regulatory dependencies

3 verified
Drugs Price Control Order, 2013
Interpretation: a change in drug price control would move formulation revenue, because the company lists this order among its applicable laws. The excerpt does not quantify the effect.
New or updated laws and regulations
Company states that failing to adapt processes to new or updated laws can pose risks, so a rule change moves compliance cost and continuity of sales.
Export incentive schemes (MEIS and FPS)
Export benefit entitlements under government schemes are recognised in the period they are approved, so a change in these schemes moves recognised other income.

Sensitivities

4 verified
USD/EUR/GBP exchange rates
Per the sensitivity table, a 1% increase in the USD rate gives a gain of 132.68 in profit and loss at 31.03.2025, and a 1% decrease gives a loss of (132.68). Euro and GBP sensitivities are shown in the same table.
Interest rates on borrowings
Interpretation: working capital interest is a major finance cost, so rate moves change finance cost. Working capital facility interest was 487.84 in FY2025 against 1,055.73 in FY2024.
Raw-material price volatility
Company states it books raw materials up-front based on customer orders and holds stock at set levels to mitigate price volatility. Interpretation: price moves hit margin on orders not yet booked.
1 more statement
Economic and political instability in import and export markets
Company states economic disruption or political change could impact the business adversely, since it imports raw materials and exports products.

Cost inputs

4 verified
Raw materials sourced from international markets
Company states its production process depends on various raw materials sourced from international markets.
Quality control and research and development
Expense line of 4,538.22 lakhs in the standalone statement for FY2025 against 1,025.94 lakhs in FY2024.
Salaries, wages, allowances and bonus
Employee cost line of 9,247.97 lakhs in FY2025 against 9,620.09 lakhs in FY2024.
1 more statement
Commission and brokerage
Selling-cost expense line of 394.65 lakhs in FY2025 against 204.33 lakhs in FY2024.

Geographies

2 verified
Europe
Revenue of 30,081.64 lakhs in FY2025 against 22,540.22 lakhs in FY2024. Company states Europe remains a core focus.
Emerging markets
Company lists Brazil, South Africa, Russia, the Gulf, Argentina, Kenya, Kazakhstan and the Philippines among its markets.
Each statement is checked word for word against the FY2025 annual report; the passages are in the app.

What changed recently?

Q1 FY2027 results filed (5 Aug 2026).

Change log

6 entries · newest first
  1. Results filedQ1 FY2027 results filed.
  2. Results filedQ4 FY2026 results filed.
  3. Results filedQ3 FY2026 results filed.
  4. Results filedQ2 FY2026 results filed.
  5. Results filedQ1 FY2026 results filed.
  6. Results filedQ4 FY2025 results filed.
Get alerts →Sign in to be told when any of these change.

What this page does not tell you

What could not be judged, and why. Never empty.
  • Models not runFair value, EPV, Graham number, Graham value, Lynch, Owner earnings: no valuation stored.
  • FlagsCLEAN on 30 of 30 flags judged; no red flag.
  • Data gapsPEG on our 3-year EPS growth, Business quality, Profit 3 years, EPS 3 years: not available yet.

What this page rests on

✓10 years of annual statements, through FY2026 (Mar-26)✓10 quarters of results✓199 months of month-end prices, adjusted for bonuses and splits○no valuation of ours yet✓business-model card FY2025 · 37 verified

Questions people ask

What is Shilpa Medicare's share price today?

Shilpa Medicare last traded at ₹1,013.90 on the NSE, as of 12 Oct 2026, 11:00 pm IST, down 0.8% on the day, up 179.8% over a year. Its 52-week range is ₹260 to ₹1,095. The live price is in the app.

What is Shilpa Medicare's market cap?

Shilpa Medicare's market capitalisation is about ₹19,983 crore: what it would cost to buy every share at today's price. That makes it the 121st largest small cap company we cover.

Is Shilpa Medicare Ltd a large cap, mid cap or small cap?

Shilpa Medicare Ltd (SHILPAMED) is a small cap company in AMFI's classification for Jan-Jun 2026. SEBI's buckets go by rank on six-month average market capitalisation: the top 100 are large caps, 101 to 250 mid caps, the rest small caps.

What is Shilpa Medicare Ltd's P/E ratio?

65.08, vs peers 41.9 · 16th of 22. Price divided by last year's earnings per share: how many years of today's profit you pay for.

Is Shilpa Medicare Ltd overvalued?

Fair, with low confidence: no valuation within 120 days; P/E 65.1 vs peers 41.9 (16th of 22); P/B 2.5 vs peers 5.4 (4th of 25).

How does Shilpa Medicare Ltd make money?

Shilpa Medicare sells pharmaceutical formulations, including oral films and transdermal patches, and power, and it also licenses out generic formulations to partners for commercialisation in international markets. Per the filings, its customers include wholesalers, distributors, pharmacy chains, hospitals and government institutions, with exports at 91.58% of turnover.

Who are Shilpa Medicare Ltd's peers?

Compared with 24 Pharmaceuticals: J B Chemicals & Pharmaceuticals Ltd, Emcure Pharmaceuticals Ltd, Wockhardt Ltd, Sai Life Sciences Ltd, Neuland Laboratories Ltd and 19 more. The app shows how they compare on every figure.

Is this investment advice?

No. Valarth is a research and learning tool and is not a SEBI-registered investment adviser or research analyst. The figures come from the company's filings and the exchanges; what to do with them is your call.

How did Shilpa Medicare do last quarter?

Shilpa Medicare reported revenue of ₹466 Cr, up 19.6% on a year earlier and a net profit of ₹101 Cr, up 210.8% in the Jun 2026 quarter.

Who owns Shilpa Medicare?

Shilpa Medicare is held by promoters 40.1%, foreign institutions 12.1%, domestic institutions 8.3%.

Does Shilpa Medicare pay a dividend?

Yes. Shilpa Medicare's dividend yield is 0.17% at the latest price; the last payout was ₹0.60 a share, ex-dividend 4 Sep 2026.

What do analysts say about Shilpa Medicare?

4 analysts cover Shilpa Medicare, and the consensus is buy. A consensus is a count of opinions, not a forecast; read it beside the numbers.

Everything on Shilpa Medicare, and 6,621 other companies, with 212 filters and the full peer tables

See Shilpa Medicare in the app →See pricing